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A new single nucleotide polymorphism in the insulin-like growth
factor I regulatory region associates with colorectal cancer risk in
singapore chinese
Abstract
Elevated levels of plasma insulin-like growth factor I (IGF-I) are a potential risk factor for several
cancers, including colorectal cancer. Physiologic levels of plasma IGF-I vary greatly; this variation may
be in part genetically determined. We identified two single nucleotide polymorphisms (SNP) in perfect
linkage disequilibrium with each other and in partial linkage disequilibrium with a previously studied
cytosine-adenine microsatellite [-969(CA)(n)]. We investigated one of the SNPs, -533T/C,and the
969(CA)(n) in relation to the risk of colorectal cancer in a case-control study nested within a cohort of
Singapore Chinese (cases/controls = 290:873). The (CA)(21) allele, rather than the previously
implicated (CA)(19) allele, was associated with a reduced risk of colorectal cancer (odds ratio for 21/21
versus all other genotypes, 0.48; 95% confidence interval, 0.28-0.84). For the -533C/T SNP, persons
carrying one or more copies of the C allele had a decreased in risk of colorectal cancer compared with
noncarriers (odds ratio for CC/CT versus TT, 0.58; 95% confidence interval, 0.41-0.82). This
association was specific for colon, as opposed to rectal cancer and was modified by age. We also
examined a functional insulin-like growth factor binding protein (IGFBP3) promoter SNP, -202 A/C,
previously reported to predict serum IGFBP3 levels. Although we were able to confirm this
genotype-phenotype association, the -202A/C IGFBP3 SNP was not significantly associated with
colorectal cancer risk. In conclusion, we report a novel SNP in the IGF-I regulatory region that is
associated with colorectal cancer risk.
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Abstract
Elevated levels of plasma insulin-like growth factor I (IGF-I)
are a potential risk factor for several cancers, including
colorectal cancer. Physiologic levels of plasma IGF-I vary
greatly; this variation may be in part genetically determined.
We identified two single nucleotide polymorphisms (SNP)
in perfect linkage disequilibrium with each other and in
partial linkage disequilibrium with a previously studied
cytosine-adenine microsatellite [-969(CA)n]. We investigated
one of the SNPs, -533T/C, and the 969(CA)n in relation to the
risk of colorectal cancer in a case-control study nested within
a cohort of Singapore Chinese (cases/controls = 290:873). The
(CA)21 allele, rather than the previously implicated (CA)19
allele, was associated with a reduced risk of colorectal cancer
(odds ratio for 21/21 versus all other genotypes, 0.48; 95%
confidence interval, 0.28-0.84). For the -533C/T SNP, persons
carrying one or more copies of the C allele had a decreased in
risk of colorectal cancer compared with noncarriers (odds
ratio for CC/CT versus TT, 0.58; 95% confidence interval,
0.41-0.82). This association was specific for colon, as opposed
to rectal cancer and was modified by age. We also examined a
functional insulin-like growth factor binding protein
(IGFBP3) promoter SNP, -202 A/C , previously reported to
predict serum IGFBP3 levels. Although we were able to
confirm this genotype-phenotype association, the -202A/C
IGFBP3 SNP was not significantly associated with colorectal
cancer risk. In conclusion, we report a novel SNP in the IGF-
I regulatory region that is associated with colorectal cancer
risk. (Cancer Epidemiol Biomarkers Prev 2005;14(1):144–51)
Introduction
Insulin-like growth factor I (IGF-I) is a cellular survival factor
implicated in various neoplasia (reviewed in refs. 1-3),
including colorectal cancer (reviewed in refs. 4, 5). IGF-I is
strongly mitogenic in colon cancer cell lines (6-8) as well as
antiapoptotic in colonic epithelial cells (9) and cancer cell lines
(10, 11). These potential carcinogenic IGF-I effects may be, in
part, exerted through hepatic-derived circulating levels
(reviewed in ref. 12). More than 75% of serum IGF-I circulates
as complexes with its predominant binding protein, IGFBP3
(13). The sequestering of IGF-I by IGFBP3 modulates IGF-I
bioavailability. In addition, many in vitro studies indicate that
independent of IGF-I, IGFBP3 inhibits replication and pro-
motes apoptosis (14, 15).
Circulating IGF-I promotes colonic carcinogenesis, as
evidenced by animal models and human studies. In mice,
circulating levels of IGF-I regulate colon cancer growth and
metastasis (16). Among human prospective studies, although
two studies failed to find an association, (17, 18), two studies
(19, 20) found a clear association between elevated plasma
IGF-I (adjusted for IGFBP3 levels) and increased colorectal or
colon cancer risk, and two found positive associations of
borderline significance (21, 22).
Twin studies suggest that circulating IGF-I and IGFBP3
levels are, in part, genetically determined (23, 24). The only
identified candidate polymorphism for IGF-I levels is a
cytosine-adenine (CA) microsatellite polymorphism, 969 kbp
upstream from the IGF-I transcription start site (25, 26), having
15 to 23 CA repeats in the Caucasian population. An initial
small study (n = 116) reported lower circulating IGF-I levels
among individuals homozygous for the (CA)19 allele versus
individuals with all other genotypes (129 versus 154 ng/mL,
P = 0.03; ref. 27). For IGFBP3, alleles of an IGFBP3 promoter
region single nucleotide polymorphisms (SNP, -202A/C) differ
in transcriptional capacities (28) and plasma IGFBP3 levels
consistently correlate with genotype in the predicted direction
(28-30).
In this study, we examine polymorphisms in the IGF-I and
IGFBP3 genes in relation to plasma levels of the respective
gene products and in relation to colorectal cancer risk in a case-
control study nested within a prospective cohort of 63,257
Singapore Chinese.
Materials and Methods
Study Population. The subjects were participants of the
Singapore Chinese Health Study, a population-based, prospec-
tive investigation of diet and cancer risk. Between April 1993
and December 1998, we recruited 63,257 Chinese men and
women from two major dialect groups in Singapore (Hokkien
and Cantonese) who originated from geographically contigu-
ous regions in Southern China: the Hokkiens from the
southern part of Fujian Province and the Cantonese from
the central region of Guangdong. Subjects were between the
ages of 45 and 74 years and resided in government housing
estates. Eighty-six percent of the Singapore population lived
in such facilities. Eighty-five percent of eligible subjects
were enrolled. The gender-dialect breakdown is as follows:
15,617 (25%) Hokkien men, 18,356 (29%) Hokkien women,
12,342 (19%) Cantonese men, and 16,942 (27%) Cantonese
women. Cohort members were comparable with the general
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Chinese population in Singapore with respect to two factors,
level of education and smoking status, for which governmen-
tal data were available. According to a 1992 national survey,
31% of Chinese men ages 45 to 69 years were current smokers,
and they smoked an average of 17 cigarettes per day. The
corresponding figures based on male cohort members are
32%, and 16, respectively. The 1990 Singapore Census data
show that 74% of Chinese ages 45 to 74 years achieved no more
than a primary school education. The corresponding figure
from our cohort is 72%.
Each subject completed a structured questionnaire given in
person by a trained interviewer. Current diet was assessed
using a validated 165-item, semiquantitative food frequency
questionnaire. Personal intakes of 96 nutritive/nonnutritive
dietary components were computed using the Singapore Food
Composition Table (31). Apart from dietary history, the
questionnaire also elicited information on lifetime tobacco use,
usual physical activity, medical history, family history of cancer,
and menstrual and reproductive history (women only).
A 3% random sample of study participants and all incident
colorectal cancer cases were contacted for biospecimens (blood
or buccal cells and single-void urine specimens) collection as
previously detailed (32). Briefly, between April 1994 and July
1999, of an estimated 1898 cohort participants contacted, blood
(n = 908) or buccal cells (n = 286) were collected from 1,194
subjects, representing a participation rate of 63%. Additionally,
beginning in January 2000, biospecimen collection was
extended to all surviving members of the cohort and is
expected to be complete by May 2004.
Controls. Of the 1,194 randomly sampled subjects who
donated biospecimens (908 blood and 286 buccal samples), 13
had developed incident colorectal cancer by April 30, 2002. The
895 (908 minus 13) cohort subjects for whom blood was drawn
and who were free of a history of colorectal cancer on April 30,
2002 comprised the comparison group for this case-control
analysis.
Cases. Incident colorectal cancer cases were identified by
record linkage with the population-based Singapore Cancer
Registry (33). The Singapore Cancer Registry was established
in 1968 and since then, has been continuously included in the
‘‘Cancer Incidence in Five Continents’’ serial publications by
the IARC in Lyon, France. Migration out of Singapore,
especially among housing estate residents, has been negligible
since inception of the cohort (Department of Statistics,
Singapore Ministry of Trade and Industry, 2001).
As of April 30, 2002, 592 cases of incident colorectal
cancer (International Classification of Diseases for Oncology
C18-C20) had developed among cohort members. Blood (n =
228) or buccal (n = 84) specimens were available on 53%
(312 of 592) of the colorectal cancer cases. Of the 312
available biospecimens, 50 were collected prediagnostically
(13 were from the 3% random sample and 37 were from the
expanded biospecimen collection after January 2000, de-
scribed above). Of the 262 (312 minus 50) cases that were
collected postdiagnostically, median time from diagnosis to
blood draw was 9.5 months.
Participants who donated biospecimens were comparable
to nondonors with respect to body mass index [body mass
index expressed as weight (kg)/height (m2)], family history
of colorectal cancer, smoking history (never, ex-smoker, and
current smoker) and physical activity (moderate activity: 0,
0.5-3, >4 hours/wk). Compared with those who had no
formal education, a higher proportion of subjects who had
primary school or higher education donated a blood or
buccal cell specimen (56% versus 46%). More male cases
donated specimens (56%) compared with females (49%), and
more Cantonese (57%) donated specimens compared with
Hokkiens (50%). The average age at diagnosis of cancer was
comparable between cases with and without specimens (65
versus 66 years).
Histologic information on each colorectal cancer diagnosis
was confirmed by reviewing the pathology report. The cases
included one carcinoid tumor, two in situ cases, and three with
unknown histologies but ascertained by death records and
clinical evidence. Because these cases are unlikely to differ
etiologically from carcinomas and because excluding these
cases did not alter the results, these six cases were retained in
our analyses.
The study protocol was approved by the Institutional
Review Boards of the University of Southern California and
the National University of Singapore. All participants gave
written, informed consent at the time of recruitment and at
collection of blood (or buccal cells) and urine specimens.
Laboratory Methods. DNA was purified from buffy coats of
peripheral blood and from buccal cell samples using standard,
published methods (34). All three genotype assays described
below were done with case-control status blinded to the
laboratory technician. Six percent of the samples were
replicated as blind duplicates distributed across all genotyping
batches. At least three negative controls (water blanks) were
included on each PCR plate. Genotyping failure rate was <2%
for each of the two IGF-I loci and 6% for the IGFBP3 SNP.
Samples with genotyping failure for one or both of the IGF-I
loci were excluded, leaving 290 cases and 873 controls. In
addition, in Table 6 and Fig. 2, an additional 18 cases and 52
controls having missing IGFBP3 genotypes were excluded.
IGF-I Promoter Region Sequencing. To identify additional
common polymorphisms in the IGF-I 5V untranslated region,
the 1 kb region spanning the (CA) repeats and the IGF-I
translation start site was resequenced for 60 Singapore
Chinese and 96 non-Hispanic White, Black, and Hispanic
White subjects (192 total chromosomes) from the Hawaii/
Los Angeles Multiethnic Cohort (35). Two overlapping
segments were amplified using two sets of primers:
5V-AATTGTTTGCCCCCCA-3V and 5V-GAACCCTGTCAC-3V
and 5V-CCCATCCCCCATATTCCT-3V and 5V-GTGCTG-
CTTTTGTGATTTC-3V. Sequencing was carried out using an
ABI Prism 3700 DNA Sequencer (PE Biosystems, Foster
City, CA).
Genotyping
IGF-I-969(CA)n. The genomic region containing the CA
repeat was PCR amplified using previously described
oligonucleotides (27). The 33P-labeled PCR products were
separated on 6% denaturing polyacrylamide gels and
visualized by autoradiography. Genotypes were scored by
comparison with controls that had genotype confirmed by
sequencing. Genotypes were independently scored by two
investigators, and samples for which there were discrepant
readings were reassayed.
IGF-I-533T/C. Alleles for the C ! T polymorphism at
position -533 upstream of the transcription start site of the
IGF-I gene (Genbank accession no. S85346) were identified by
the fluorogenic 5V-nuclease assay (Taqman Assay; ref. 36) using
the Taqman PCR Core Reagent Kit (Applied Biosystems, Foster
City, CA) according to manufacturers’ instructions. The
oligonucleotide primers for amplification of the polymorphic
region were GC029 for (5V-gcccctccataggttctagga-3V) and GC029
rev (5V-cgggtgaccccttgtcc-3V). Fluorogenic oligonucleotide
probes used to detect each of the alleles were GC029F
(5V-agatcacacccctcacttggcaac-3V) labeled with 6-FAM and
GC029 C (5V-agatcacacctctcacttggcaac-3V) labeled with CY3
(BioSearch Technologies, Novato, CA). PCR amplification
was done in a thermal cycler (MWG Biotech, High Point,
NC) with an initial step of 95jC for 10 minutes followed by
50 cycles of 95jC/25 seconds and 63jC/1 minutes. The
fluorescence profile of each well was measured in an ABI 7900
HT Sequence Detection System (Applied Biosystems) and the
results analyzed with Sequence Detection Software (Applied
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Cancer Epidemiol Biomarkers Prev 2005;14(1). January 2005
Biosystems). Any samples that were outside the variables
defined by the controls were identified as noninformative.
IGFBP3-202A/C. Alleles for the A ! C polymorphism at
position. -202 of the IGFBP3 gene were identified using direct
sequencing of the polymorphic region. The region of the gene
containing the polymorphism was amplified by PCR using
primers GC082 for (5V-GAGTTGGCCAGGAGTGACTG-3V)
and GC082 rev (5V-GCGTGCAGCTCGAGACTC-3V). PCR
reaction mix was prepared using HotStart Taq Polymerase
(Qiagen, Valencia, CA) according to manufacturers’ instruc-
tions using 20 ng of genomic DNA, 2 mmol/L MgCl2, and 300
mol/L of each primer. PCR amplification was done in a
thermal cycler (MWG Biotech) using a touchdown protocol
with an initial step of 95jC for 15 minutes finishing with 35
cycles of 95jC/25 seconds, 57jC/1 minute, and 72jC/1
minute. DNA sequencing was done using primer GC082S
(5V-CCAGGAGTGACTGGGGTGA-3V) using f10 to 20 ng of
purified PCR product using fluorescently labeled dideoxynu-
cleotide triphosphates (ABI Dye Terminator Sequencing Kit,
Applied Biosystems) by cycle sequencing for 50 rounds of
95jC/15 seconds and 58jC/3.5 minutes. The sequencing
reactions were run on an ABI3700 Capillary DNA Analyzer.
Serum Assays. Total serum IGF-I and IGFBP3 levels were
measured as previously described (17). Briefly, measurements
of serum IGF-I and IGFBP3 concentrations were carried out
using immunoradiometric assay kits (Diagnostic Systems
Laboratories, Inc., Webster, TX), following the instructions of
the manufacturer.
Statistical Analysis
Genotype-Colorectal Cancer Risk Association. Although we
sampled our controls from the whole cohort, this study is
more case-control than case-cohort in design because the time
period of follow-up was comparable between the cases and
subcohort, with only 13 subjects in the latter group developing
colorectal cancer during the observation period. Nonetheless,
parallel analyses were conducted using standard case-control
and case-cohort methods and did not materially differ. The
data presented in this manuscript are based on case-control
analysis.
Specifically, to assess the extent of cancer risk associated
with genotypes, unconditional multiple logistic regression
models (37) were fitted and odds ratio (OR) and their
corresponding 95% confidence intervals (95% CI) were
reported. All logistic regression models included age at
recruitment (continuous), year of recruitment, gender, and
dialect group (Cantonese, Hokkien) as covariates. Colorectal
cancer risk factors which were considered as potential
confounders were body mass index, height, education levels,
alcohol intake, physical activity, and smoking history. None
were included in the final model because inclusion did not
substantially alter (>5%) the variable estimates for the
exposures (genotypes).
Colorectal cancer was coded by anatomic subsites per the
International Classification of Disease Oncology (2nd ed.): colon
(C18.0-C18.9) and rectal (C19.0-C20.0) cancers. To test for
heterogeneity of odds ratios across anatomic subsite as well as
age at diagnosis for cases (young cases: <60 years; old cases:
z60 years), polychotomous logistic regression models were
fitted and likelihood ratio tests were conducted.
To investigate the possible interaction of the IGF-I genotype
with gender and factors associated with serum IGF-I in this
population (body mass index, calcium intake, and physical
activity; ref. 38), the respective multiplicative interaction terms
were included in the regression models and likelihood ratio
tests were conducted for significance of the interaction
variables.
Haplotype Inference and Allelic Cosegregation/Association.
Allele frequencies were determined by gene counting (39).
The observed allele frequencies among controls were used to
calculate the expected genotype frequencies under Hardy-
Weinberg equilibrium. Departures from Hardy-Weinberg
equilibrium was assessed by testing the difference between
the observed (sampled) and expected (under Hardy-Wein-
berg equilibrium) genotype frequencies in controls using a
m2 test (40). Linkage disequilibrium (LD) between IGF-I
polymorphisms was assessed by using a m2 test of allelic
association (41).
To estimate haplotype frequencies from genotype informa-
tion within our population of unrelated individuals, we used
the expectation-maximization algorithm, as implemented in
the STATA command hapipf, to resolve phase uncertainties
(42–44). To estimate ORs for haplotype combinations, each
individual in the sample was replicated for all possible
haplotype configurations that are compatible with their
genotypes and weighed by the estimated haplotype frequen-
cies in logistic regression models (45).
Genotype-Phenotype Association. Of the 895 controls in this
study, 628 had serum IGF-I and 595 had serum IGFBP3
measurements available (described previously by Probst-
Hensch et al. 38). Kruskal-Wallis test statistics were used to
compare distributions of the serum markers by genotype
categories. Multiple regression models were also fitted with
age, sex, body mass index, dialect group, and year of
recruitment as covariates but were not reported as none of
these nongenetic risk factors acted as confounders.
All Ps are two sided and statistical analyses were done
using STATA 8.0 (Stata Co., College Station, TX).
Results
Study Characteristics. The baseline characteristics of the
Singapore Chinese Health Study cohort have been described
(32). Briefly, the mean age of cohort subjects at enrollment was
56.5 years. Fifty-six percent of cohort subjects were women and
54% belonged to the Hokkien dialect group. Most were
married (83%) at the time of recruitment. Eighty-eight percent
of cohort subjects were born in Singapore or Malaysia
(Singapore and Malaysia are neighboring countries with
similar sociocultural groups), whereas virtually all of the
remaining 12% were born in China. The cohort was relatively
uneducated; 27% of its members had no formal education and
44% received only a primary school education.
The control group for this study was comparable to the
whole cohort with respect to demographic variables and colon
cancer risk factors. Table 1 summarizes the demographic
characteristics among cases and controls. Cases were heavier
than controls, marginally taller, less educated, and more likely
to be male. Controls and cases did not differ significantly in
terms of physical activity, dietary calories, fat, fiber, or
calcium. In addition, they did not differ by dialect group,
family history of colon or rectal cancer, smoking, alcohol
consumption, age at menarche, age at menopause, parity, or
age at first birth (data not shown). The age at diagnosis for
cases ranged from 47 to 82 years (median, 66 years).
IGF-I -969(CA)n Genotypes. Eleven alleles, having 12 to 23
repeats, were observed in the Singapore Chinese population
(Table 2). The (CA)19 allele, at 35.5%, the most frequent among
both cases and controls, is the most common allele in
previously reported Caucasian (62.1-67.9%, refs. 46, 47),
Japanese (40.8%, ref. 48), Indian Pakistani (56%) and African
American (37.8%, ref. 30) populations. Although alleles (CA)18
and (CA)19 seemed to be slightly more common among cases
and allele (CA)21 was more common among controls, there
was no overall significant difference in the genotype distribu-
tions between cases and controls (P = 0.12).
Genotype distributions did not deviate from Hardy-
Weinberg expectations. Table 3 shows the ORs for allele
19, the allele previously associated with lower levels of
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circulating IGF-I (27, 30), and for the next most common
allele, (CA)21 . There was no decrease in risk among those
who carried one or two copies of the (CA)19 allele. Given the
previously reported lower levels of circulating IGF-I only
among homozygous carriers of the (CA)19 allele, we also
combined heterozygotes and noncarriers. No decreased risk
was observed for genotype 19/19 versus others. For the
second most common allele, (CA)21 , possession of two
copies was associated with approximately half of the risk
for colorectal cancer compared with all other genotypes
(Table 3).
IGF-I -533T/C Genotypes. Resequencing revealed two
previously unreported SNPs (-533T/C and -484T/A) in perfect
LD with each other (Fig. 1). We genotyped one of the SNPs, -
533T/C, for all cases and controls. Genotype frequencies were
in agreement with Hardy-Weinberg equilibrium.
Table 4 summarizes the effect of the 533T/C genotype on
colorectal cancer risk. An f30% decrease in risk was
associated with possession of one or two copies of the C allele
as compared with genotype TT . This association was confined
to risk of colon cancer.
The effect of the C allele seemed to be modified by age, a
strong predictor of circulating IGF-I levels in adulthood (49-51).
It was primarily among young participants (below age 60
years) that the protective effect of the C allele was observed.
Young carriers of the C allele had a 54% reduction in risk of
colorectal cancer (Table 4). In addition, the effect of the -533T/C
genotype on colorectal cancer risk was stronger in overweight
persons (i.e., body mass index = 24 kg/m2; TT versus CT/CC:
OR, 0.48; 95% CI, 0.29-0.79) as contrasted to lean persons (i.e.,
body mass index < 24 kg/m2; TT versus CT/CC: OR, 0.83; 95%
CI, 0.58-1.17) with a nearly significant formal test for interaction
(P = 0.08). There was no evidence of interaction by gender,
calcium intake, or physical activity.
IGF-I Haplotypes. The -969(CA)n and -533T/C loci were not
independently distributed (P < 0.001). The frequency of the
(CA)21- C haplotype was higher than expected under the
hypothesis of no LD (25.1% versus 17.5%; Table 5). Seventy-
five percent (439 of 584) of the C alleles were observed to be
linked to the (CA)21 allele. The T allele, on the other hand, was
more often associated with alleles (CA)17 to (CA)19 . Only 8%
(97 of 1,162) of T alleles were linked to (CA)21.
We estimated ORs for the (CA)21 C haplotype, the
haplotype carrying the two alleles, (CA)21 and -533 C , that
Table 1. Selected characteristics of colorectal cancer cases and controls, Singapore Chinese Health Study
Characteristics Controls Cases P
Total no. 873 (100)* 290 (100)*
Sex
Female 492 (56.4) 122 (42.0) <0.01
Male 381 (43.6) 168 (58.0)
Body mass index (kg/m2)
V20 144 (16.4)* 44 (15.2)* 0.04
20 to <24 485 (55.6)* 143 (49.3)*
24 to <28 200 (23.0)* 83 (28.6)*
>28 44 (5.0)* 20 (6.9)*
Height 160 (147,170)c 160 (147,175)c 0.01
Moderate physical activity (h/wk)
0 653 (74.8) 217 (74.8) 0.69
0.5-3 139 (15.9) 42 (14.5)
>4 81 (9.3) 31 (10.7)
Education level
High school 604 (69.2)* 193 (66.6)* <0.01
None (formal) 207 (23.7)* 87 (30)*
Post-high school 41 (4.7)* 6 (2.0)*
University 21 (2.4)* 4 (1.4)*
Total calcium intake (mg/d) 388.7 (160.1, 865.0)c 364.8 (149.3, 781.8)c 0.20
Total calories (kcal/d) 1,494.5 (835.6, 2,480.2)c 1,497.4 (814.4, 2,583.0)c 0.91
Total fiber intake (g/d) 12.3 (5.3, 23.7) 11.9 (4.2, 22.7) 0.54
Total fat (g/d) 41.4 (19.7, 82.3)c 39.5 (18.3, 77.2)c 0.20
*Number of subjects (%).
cMedian (5th, 95th percentile).
Table 2. Distribution of the -969(CA)n allele frequencies in
Singapore Chinese
Cytosine-adenine repeats Controls (%) Cases (%)
12 7 (0.4) 3 (0.5)
14 1 (0.1) 0 (0)
15 2 (0.2) 0 (0)
16 6 (0.3) 0 (0)
17 133 (7.6) 50 (8.6)
18 279 (16.0) 112 (19.3)
19 620 (35.5) 215 (37.1)
20 100 (5.7) 38 (6.6)
21 536 (30.7) 151 (26.0)
22 56 (3.2) 10 (1.7)
23 6 (0.3) 1 (0.2)
Table 3. ORs and 95% CIs for the -969(CA)n polymorphism
and colorectal cancer, Singapore Chinese Health Study
Genotype Controls/cases
(n = 873/n = 290)
OR (95% CI)*
Repeat 19
Others 374/110 1.00 (reference)
(CA) 19/others 378/145 1.33 (0.98-1.80)
(CA)19/(CA)19 121/35 1.03 (0.64-1.63)
(CA)19/(CA)19
versus all other
genotypes
0.88 (0.57-1.36)
Repeat 21
Others 426/157 1.00 (referent)c
(CA)21/others 358/115 0.90 (0.67,1.23)c
(CA)21/(CA)21 89/18 0.46 (0.26,0.81)c
(CA)21/(CA)21
versus all other
genotype
0.48 (0.28,0.84)
*Adjusted for age at recruitment (continuous), sex, dialect group (Cantonese or
Hokkien), and year of recruitment.
cP for trend = 0.02.
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were univariately associated with lower risk. Compared with
those carrying no copies of the (CA)21 C haplotype, ORs for
those carrying one or two copies were 1.00 (95% CI, 0.74-1.36)
and 0.63 (95% CI, 0.34-1.15), respectively.
IGFBP3 -202 A/C. Allele frequencies among control subjects
for the -202A/C polymorphism were 77% and 23%, respective-
ly, for the A and C alleles. Genotype frequencies did not
deviate from Hardy-Weinberg expectations. Overall, the
genotypes were not associated with colorectal cancer risk
(Table 6). However, there was evidence of heterogeneity by
anatomic site (P = 0.04). This result seemed to be driven by the
relatively small number of subjects with genotype CC .
Compared with persons carrying at least one copy of the A
allele, persons homozygous for the C allele had a nonstatisti-
cally significantly increased risk of colon cancer and a
nonstatistically significantly decreased risk of rectal cancer.
There was no evidence of heterogeneity by age or interaction
with body mass index, gender, calcium intake, or physical
inactivity.
Gene-gene Interaction. There was no evidence that the
relationship between IGF-I genotypes [-969(CA)19, -969(CA)21 ,
and -533T/C) and colorectal cancer risk was modified by
IGFBP3 genotype (-202A/C).
Genotype-Phenotype Analyses
IGF-I Genotypes and Serum IGF-I Levels. In the IGF-I gene, the
969(CA)n , and in particular the two most common alleles
(CA)19 and (CA)21 , did not predict serum IGF-I among the
628 controls with serum levels available. Median values for
(CA)19/19 , (CA)19/others , (CA)others/others were 125, 132, and 127
ng/mL, respectively (P = 0.56). Median values for (CA)21/21 ,
(CA)21, (CA)others/others were 127, 130, and 127 ng/mL,
respectively (P = 0.87).
Neither did the -533T/C SNP predict serum IGF-I levels.
Median values for the CC, CT , and TT genotypes were 130,
133, and 122 ng/mL, respectively (P = 0.35).
IGFBP3 Genotype and Serum IGFBP3 Levels . The -202A/C SNP
in the IGFBP3 gene was associated with serum IGFBP3 levels
in the predicted direction (Fig. 2). Median serum IGFBP3 levels
were 3,994, 3,785, and 3,307 ng/mL for genotypes AA, AC , and
CC , respectively (P < 0.001).
Discussion
In this study, we examined polymorphisms in the IGF-I and
IGFBP3 genes in a cohort of Singapore Chinese. We identified
two new IGF-I promoter region SNPs, in LD with a CA
microsatellite that, in previous studies, has been inconsistently
associated with cancer risk and other phenotypes. We report
here that the new polymorphisms are associated with risk of
colorectal cancer, specifically in the colon. We also report that
IGFBP3 genotype, whereas not related to risk of colorectal
cancer, is a predictor of serum IGFBP3 levels.
IGF-I Genotype. Previous studies do not support a direct
functional effect of the CA microsatellite polymorphism.
Although lower serum IGF-I levels among men with the
(CA)19/19 genotype were initially reported in a small study of
men with idiopathic osteoporosis (n = 116; ref. 27), three
prospective studies, the United Kingdom component of EPIC
(n = 660, ref. 46), the Nurses’ Health Study (n = 202 controls
refs. 52, 53), and the Hawaii/Los Angeles Multiethnic Cohort
(n = 230 ref. 35), found no association between CA genotype
and serum levels. Two other large studies reported an
association between genotype and serum levels; however,
results were in opposing directions. Reduced circulating IGF-I
levels were associated with the absence of the (CA)19 (n = 900,
P = 0.003; ref. 54) in a Dutch population and with the
presence of the (CA)19 allele (n = 640, P trend = 0.01; ref. 47) in
a study in South Wales. Whereas the results of these latter
two studies suggest that polymorphism at this locus
influences serum IGF-I levels, the conflicting direction of
the results suggest that it is not the CA microsatellite
polymorphism that is responsible (47).
To explore the possibility that the CA microsatellite is a
marker of a functional polymorphism, we resequenced the
promoter region of the IGF-I gene from the CA microsatellite to
the translation start site. We identified two new SNPs (-533T/C
and -483A/T) that are in partial LD with the -969(CA)n . Because
the two new SNPs are in perfect LD, only one of the SNPs (i.e.,
-533T/C) was examined in the current study. The C allele of the
-533T/C SNP was partially linked with the (CA)21 allele and
both were associated with colorectal cancer risk in this study. In
addition, the (CA)21- C haplotype also predicted lower risk but
was not more informative than either of the single markers.
Possible scenarios are that either the new SNP is causal or it is
in tighter LD with the putative causal SNP than is the
haplotype marker. Indeed, due to the hypermutable nature of
Figure 1. Insulin-like growth factor I promotes polymorphisms.
Table 4. ORs and 95% CIs for the IGF-I -533T/C genotype
and colorectal cancer, Singapore Chinese Health Study
Genotype Controls (%) Cases (%) OR (95% CI)*
TT 390 (44.7) 156 (53.8) 0.68 (0.50,0.93)
CT 382 (43.8) 101 (34.8) 0.68 (0.50,0.93)
CC 101 (11.5) 33 (11.4) 0.71 (0.44,1.13)
CC/CT vs. TT 0.69 (0.52,0.92)
Subsite
Colon
TT 390 (44.7) 99 (58.9) 1.00 (reference)
CT 382 (43.8) 54 (32.2) 0.59 (0.40-0.86)
CC 101 (11.5) 15 (8.9) 0.54 (0.29-0.99)
CC/CT versus TT 0.58 (0.41-0.82)
Rectal
TT 390 (44.7) 57 (46.7) 1.00 (reference)
CT 382 (43.8) 47 (38.5) 0.91 (0.59-1.37)
CC 101 (11.5) 18 (14.8) 1.08 (0.60-2.00)
CC/CT versus TT 0.94 (0.63-1.40)
P for heterogeneity = 0.04c
Age at diagnosis
<60 y
TT 390 (44.7) 45 (62.5) 1.00 (reference)
CT 382 (43.8) 20 (27.8) 0.42 (0.24-0.74)
CC 101 (11.5) 7 (9.7 ) 0.61 (0.28-1.43)
CC/CT versus TT 0.46 (0.28-0.76)
z60 years
TT 390(44.7) 111(50.9) 1.00 (referent)
CT 382(43.8) 81(37.2) 0.84 (0.58,1.22)
CC 101(11.5) 26(11.9) 0.74 (0.42,1.29)
CC/CT versus TT 0.81 (0.57-1.14)
P for heterogeneity = 0.06b
*OR from unconditional logistic regression; adjusted for age at recruitment,
gender, dialect groups (Cantonese or Hokkien), and year of recruitment
(continuous).
cThe odds of the cases carrying the IGF1 genotype TT compared to the
combined genotypes of CT/CC were contrasted between colon cancer and rectal
cancer cases.
bTest of heterogeneity comparing odds ratio of carriers of TT versus CT/CC
among younger and older cancer cases.
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microsatellites (55, 56), the haplotype marker may contain
more measurement error.
Although it is possible that the -533T/C SNP is directly
responsible for the observed association, there is currently no
evidence that it has a functional effect. In fact, we found no
association between genotype and serum levels. Whereas
measurement of IGF-I serum levels can be problematic due
to variable cleavage products in stored specimens (57), IGF-I
serum levels have been associated with colorectal cancer risk
in some previous studies. The reason for the lack of association
between the SNP and IGF-I serum levels in this population
remains unresolved.
The -533T/C SNP was primarily associated with risk of colon
but not rectal cancer. Consistent with our findings, elevated
serum IGF-I levels have been associated with risk of colon but
not rectal cancer in a cohort of Hawaiian Japanese (20). Colon
and rectal cancer incidence differ in distribution by geography,
ethnicity, age, and gender (58), suggesting differences in
etiology between the cancers (reviewed in ref. 59). However,
heterogeneity by subsite was not observed in the Physicians’
Health Study (19), or in the two negative prospective studies
[i.e. the Shanghai Chinese Male Cohort (17) or the New York
Women’s Study (18).
We observed effect-modification by age. Levels of circu-
lating IGF-I decline with age (49-51) and the growth
hormone axis is thought to be responsible. Only among
younger persons (<60 years) was the genotypic effect
evident. Among older people, who have presumably already
undergone a significant age-related decline in serum IGF-I
levels, no effect of genotype on cancer risk was observed. A
similar pattern was seen for serum IGF-I levels in a
Hawaiian Japanese cohort (20). Furthermore, a previous
study reported an interaction between age and the -961(CA)n
genotype: the age-related decrease in circulating levels of
IGF-I was stronger among homozygotes for -961(CA)19 (60).
IGFBP3 Genotype. We confirmed that the IGFBP3 genotype
predicts serum IGFBP3 levels. Consistent with previous
studies (28-30) and with in vitro assays (28), there was a trend
for decreasing serum IGFBP3 levels with increasing copies of
the C allele. Whereas there was no significant association
between genotype and cancer risk, there was evidence of
heterogeneity by anatomic site, with a nonsignificantly
increased risk of colon cancer among subjects with genotype
CC . Larger sample sizes are needed to confirm these results.
Gene-gene Interaction. Whereas a main effect of the
IGFBP3 genotype on colorectal cancer risk in our population
was not observed, IGFBP3 genotype might plausibly influence
the effect of IGF-I genotype on cancer risk. IGFBP3 potentially
influences the effects of IGF-I on cellular growth and
proliferation through stabilizing and increasing IGF-I half-life,
modulating IGF-I transportation and cellular localization,
extending metabolic clearance and regulating IGF-I/IGF-I-
receptor binding. Although we found no evidence of gene-
gene interaction, we had very low power to conduct a formal
test of interaction.
Conclusion. Our finding of an association between genetic
polymorphism in the IGF-I promoter region and colorectal
cancer risk is unlikely to be an artifact of population
Table 5. Estimated haplotype frequencies for IGF-I -969(CA)n and -533T/C polymorphisms, Singapore Chinese Health Study
Haplotype Frequencies (%) Haplotype Frequencies (%)
Estimated* Expectedc Estimated* Expectedc
(CA)17 C 8 (0.5) 26 (1.5) (CA)17 T 125 (7.2) 106 (6.1)
(CA)18 C 18 (1.0) 64 (3.7) (CA)18 T 262 (15.0) 215 (12.3)
(CA)19 C 48 (2.7) 123 (7.0) (CA)19 T 572 (32.8) 496 (28.4)
(CA)20 C 16 (0.9) 24 (1.4) (CA)20 T 84 (4.8) 77 (4.4)
(CA)21 C 439 (25.1) 306 (17.5) (CA)21 T 97 (5.6) 230 (13.2)
(CA)22 C 50 (2.9) 35 (2.0) (CA)22 T 6 (0.3) 22 (1.3)
Other, C 5 (0.3) 6 (0.3) Other, T 16 (0.9) 16 (0.9)
Total 584 584 Total 1,162 1,162
*Estimated using the expectation-maximization algorithm to resolve phase uncertainty.
cExpected frequencies under the null hypothesis of no linkage disequilibrium.
Table 6. ORs and 95% CIs for the -202 IGFBP3 and
colorectal cancer, Singapore Chinese Health Study
Genotype Controls/Cases
(n = 821/n = 272)
OR (95% CI)*
AA 480/166 1.00 (reference)
AC 306/90 0.90 (0.66-1.23)
CC 35/16 1.27 (0.67-2.45)
CC versus AA/AC 1.32 (0.69-2.52)
Subsite
Colon
AA 480/93 1.00 (reference)
AC 306/51 0.90 (0.61-1.32)
CC 35/13 1.82 (0.89-3.74)
CC versus AA/AC 1.89 (0.94-3.82)c
Rectum
AA 480/73 1.00 (reference)
AC 306/39 0.88 (0.57-1.35)
CC 35/3 0.54 (0.56-1.35)
CC versus AA/AC 0.56 (0.17-1.91)c
P for heterogeneity=0.04c
*Adjusted for age at recruitment (continuous), sex, dialect group (Cantonese or
Hokkien), and year of recruitment.
cThe odds of the cases carrying the IGFBP3 genotype CC compared with the
combined genotypes of AA/AC were contrasted between colon cancer and rectal
cancer cases. Figure 2. Circulating levels of IGF-I by -202IGFBP3 genotype.
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stratification and admixture (61) because the Singapore Chinese
Health Study is a population-based cohort investigation
involving subjects drawn from an ethnically homogeneous
southern Chinese population. This population originates from
the contiguous coastal provinces, Fujian and Guangdong, and
forms a tight genetically homogeneous subcluster within the
relatively genetically similar Southern Chinese population (ref.
62 and references therein). Neither is selection bias likely to
explain our results since participation rate was high (85%),
participants seemed to be similar to the general population, and
biospecimen donors and nondonors differed only by dialect
group, gender, and education, none of which were related to
genotype. Furthermore, the validity of this finding is supported
by the observation that a strong predictor of serum IGF-I (age)
modifies the effect of IGF-I genotype on colorectal cancer
occurrence.
However, the identity of the polymorphism causally respon-
sible for this association has not been definitively determined.
All three makers, the (CA)21- C haplotype, the -969(CA)21 allele,
and the -533 C allele, predicted lower risk. Whereas none of
these three markers was clearly most informative, the -533 T/C
SNP has the advantages of being less prone to measurement
error (compared with a microsatellite marker), and of produc-
ing more stable (less sparse) data. Our finding of an association
between the -533 T/C SNP and colorectal cancer risk supports
the utility of this newly identified IGF-I promoter region SNP
for IGF-I association studies.
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